Skip to Content

Prochymal Approval Status

FDA Approved: No
Brand name: Prochymal
Company: Osiris Therapeutics, Inc.
Treatment for: Graft-versus-host disease

Prochymal is a preparation of mesenchymal stem cells formulated for intravenous infusion. Prochymal is currently being evaluated in Phase III trials for steroid refractory graft-versus-host disease (GvHD), acute GvHD, and Crohn's disease.

Development Status and FDA Approval Process for Prochymal

DateArticle
Jan 15, 2009Osiris and FDA Reach Agreement on Submission of First Marketing Application for a Stem Cell Product

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide